金陵药业(000919) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥746,529,645.21, representing a 5.36% increase compared to ¥708,534,720.18 in the same period last year[5] - Net profit attributable to shareholders was ¥43,544,728.75, showing a slight decrease of 0.09% from ¥43,585,110.26 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 10.14% to ¥41,424,468.75 from ¥37,611,565.58 in the previous year[5] - Total operating revenue for Q1 2024 reached ¥746,529,645.21, an increase of 5.7% compared to ¥708,534,720.18 in Q1 2023[20] - Net profit for Q1 2024 was ¥47,167,313.01, a decrease of 4.4% from ¥49,325,374.22 in Q1 2023[21] - The total comprehensive income for the first quarter was CNY 47,167,313.01, a decrease from CNY 49,325,374.22 in the previous period[22] - The net profit attributable to the parent company was CNY 43,544,728.75, slightly down from CNY 43,585,110.26 year-on-year[22] - Basic and diluted earnings per share were both CNY 0.0849, compared to CNY 0.0865 in the previous period[22] Assets and Liabilities - The company's total assets grew by 17.42% to ¥5,343,013,703.39 from ¥4,550,522,846.98 at the end of the previous year[5] - The total liabilities for Q1 2024 were ¥868,698,491.37, slightly up from ¥865,577,180.27 in the previous year[18] - The company's equity attributable to shareholders reached ¥3,828,358,928.15, an increase from ¥3,042,611,967.10 in Q1 2023, reflecting a growth of 25.8%[18] Cash Flow - The net cash flow from operating activities was negative at -¥61,243,199.22, a decline of 141.55% compared to -¥25,354,145.88 in the same period last year[5] - Cash inflows from operating activities totaled CNY 637,598,785.38, down from CNY 675,761,687.56 in the previous period[23] - The net cash flow from operating activities was negative at CNY -61,243,199.22, compared to CNY -25,354,145.88 in the previous period[23] - Cash inflows from investment activities were CNY 103,069,300.47, significantly up from CNY 2,660,810.53 in the previous period[24] - The net cash flow from investment activities was CNY -191,504,673.19, slightly improved from CNY -209,375,029.15 year-on-year[24] - Cash inflows from financing activities were CNY 742,632,289.33, a substantial increase from CNY 3,681,573.36 in the previous period[24] - The net increase in cash and cash equivalents was CNY 489,875,788.28, compared to a decrease of CNY -231,087,932.62 in the previous period[24] - The ending balance of cash and cash equivalents was CNY 1,710,278,229.98, up from CNY 1,243,795,533.31 at the end of the previous period[24] Research and Development - Research and development expenses increased by 45.99% to ¥20,776,182.16 from ¥14,231,193.78 year-on-year[8] - Research and development expenses increased to ¥20,776,182.16 in Q1 2024, compared to ¥14,231,193.78 in Q1 2023, marking a growth of 46%[20] Shareholder Information - The company reported a total of 227,943,839 shares held by its largest shareholder, Nanjing New Industry Investment Group, accounting for 44.60% of total shares[11] - Shareholders' equity attributable to the parent company increased by 25.82% to ¥3,828,358,928.15 from ¥3,042,611,967.10[5] Government and Regulatory Matters - The company received government subsidies amounting to ¥1,801,446.70, which were closely related to its normal business operations[6] - The company has signed a letter of intent for acquisition and related transactions, as announced in document 2024-001[13] - The company plans to change commitments to resolve competition issues with its controlling shareholder and its wholly-owned subsidiaries[13] - The company has appointed a new accounting firm for the fiscal year 2024[13] - The company is utilizing idle funds to purchase financial products, with progress reported in document 2024-009[13] - The company has received approval from the China Securities Regulatory Commission for a specific stock issuance[13] - The company is seeking to extend the validity period of the resolution for issuing A-shares to specific objects[13] Financial Assets and Receivables - The company reported a significant increase of 327.39% in trading financial assets, reaching ¥352,888,208.20 due to increased investments in financial products by its subsidiary[8] - Accounts receivable rose by 55.25% to ¥493,504,507.95, attributed to increased settlement amounts and enhanced credit for certain distributors[8] - Trade receivables rose to ¥493,504,507.95 from ¥317,873,734.09, indicating a significant increase of about 55.2%[16] Inventory and Compensation - The company's inventory decreased to ¥252,393,007.71 from ¥268,060,352.54, reflecting a decline of approximately 5.8%[16] - The company reported a decrease in employee compensation payable to ¥70,095,963.17 from ¥118,143,672.20 year-over-year, a reduction of 40.6%[20] - Deferred income tax assets increased to ¥13,803,010.60 in Q1 2024, compared to ¥11,050,160.77 in Q1 2023, showing a growth of 25.1%[18]